Long-term outcome of cryo-preserved bony allografts used after extensive bony resections for malignant tumors

1997 ◽  
Vol 7 (2) ◽  
pp. 111-114
Author(s):  
M. Perrin ◽  
J. Fraisse ◽  
J. Cuisenier
Keyword(s):  
Malignant Tumors ◽  
Term Outcome ◽  
Long Term Outcome

Long-Term Outcome After Endoscopic Mucosal Resection of Superficial Esophageal Malignant Tumors

2005 ◽  
Vol 61 (5) ◽  
pp. AB130
Author(s):  
Pierre H. Deprez ◽  
Tarik Aouattah ◽  
Christine Sempoux ◽  
Jacques Grodos ◽  
Rene Fiasse ◽  
...  
Keyword(s):  
Endoscopic Mucosal Resection ◽  
Malignant Tumors ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Mucosal Resection

scholarly journals Long-term prognosis of patients with pediatric pheochromocytoma

2013 ◽  
Vol 21 (1) ◽  
pp. 17-25 ◽  
Author(s):  
Birke Bausch ◽  
Ulrich Wellner ◽  
Dirk Bausch ◽  
Francesca Schiavi ◽  
Marta Barontini ◽  
...  
Keyword(s):  
Life Expectancy ◽  
Malignant Tumors ◽  
Germline Mutations ◽  
Hereditary Disease ◽  
Initial Diagnosis ◽  
Second Primary ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Long Term Prognosis

A third of patients with paraganglial tumors, pheochromocytoma, and paraganglioma, carry germline mutations in one of the susceptibility genes, RET, VHL, NF1, SDHAF2, SDHA, SDHB, SDHC, SDHD, TMEM127, and MAX. Despite increasing importance, data for long-term prognosis are scarce in pediatric presentations. The European-American-Pheochromocytoma–Paraganglioma-Registry, with a total of 2001 patients with confirmed paraganglial tumors, was the platform for this study. Molecular genetic and phenotypic classification and assessment of gene-specific long-term outcome with second and/or malignant paraganglial tumors and life expectancy were performed in patients diagnosed at <18 years. Of 177 eligible registrants, 80% had mutations, 49% VHL, 15% SDHB, 10% SDHD, 4% NF1, and one patient each in RET, SDHA, and SDHC. A second primary paraganglial tumor developed in 38% with increasing frequency over time, reaching 50% at 30 years after initial diagnosis. Their prevalence was associated with hereditary disease (P=0.001), particularly in VHL and SDHD mutation carriers (VHL vs others, P=0.001 and SDHD vs others, P=0.042). A total of 16 (9%) patients with hereditary disease had malignant tumors, ten at initial diagnosis and another six during follow-up. The highest prevalence was associated with SDHB (SDHB vs others, P<0.001). Eight patients died (5%), all of whom had germline mutations. Mean life expectancy was 62 years with hereditary disease. Hereditary disease and the underlying germline mutation define the long-term prognosis of pediatric patients in terms of prevalence and time of second primaries, malignant transformation, and survival. Based on these data, gene-adjusted, specific surveillance guidelines can help effective preventive medicine.

Long-Term Outcome of Surgically Treated Malignant Tumors of the Nasal Cavity and Paranasal Sinuses Involving Anterior Skull Base

Skull Base ◽  
2007 ◽  
Vol 17 (S 1) ◽  
Author(s):  
Takashi Tokutomi ◽  
Yueching Wong ◽  
Kikuo Sakamoto ◽  
Kiyokawa Kensuke ◽  
Tadashi Nakashima ◽  
...  
Keyword(s):  
Nasal Cavity ◽  
Skull Base ◽  
Paranasal Sinuses ◽  
Malignant Tumors ◽  
Anterior Skull Base ◽  
Term Outcome ◽  
Long Term Outcome

Long-term outcome of treatment with cyclosporine IV for patients with intractable ulcerative colitis

2001 ◽  
Vol 120 (5) ◽  
pp. A624-A624 ◽  
Author(s):  
J ARTS ◽  
M ZEEGERS ◽  
G DHAENS ◽  
G VANASSCHE ◽  
M HIELE ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Term Outcome ◽  
Long Term Outcome
Sign in / Sign up

Export Citation Format

Share Document